secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-09-09T12:10:15+00:00
Accession:  0001213900-26-098224
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics appoints former CDC Director Robert Redfield as Chief Scientific Officer
--------------------------------------------------------------------------------

- Robert R. Redfield, M.D., former CDC Director, named Chief Scientific Officer effective Sept 9, 2026.
- Redfield brings 40+ years in immunology, infectious disease; cited >40,000 times in scientific literature.
- He will lead scientific strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa.
- Redfield will work with CEO Bradley Burnam and former FDA Commissioner Stephen Hahn.
- Company is clinical-stage biotech developing non-systemic therapies for inflammatory skin diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026098224/0001213900-26-098224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026098224/ea0304806-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer